Eli Lilly’s Weight-Loss Drug Sales Miss Expectations, Shares Fall

Eli Lilly on Thursday posted better-than-expected quarterly results, although sales of its popular weight-loss drug, Zepbound, came in slightly below Wall Street estimates, sending its shares down 4% in premarket trading.